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Poster Session-I 59and IL2. Using this approach we consistently generated PRAME-
CTLs in 12/14 HLA-A*02 healthy donors (526 6 101 SFC/105
cells as assessed by IFNg Elispot assay). Similarly, PRAME-
CTLs were generated from all 5 CML patients (630 6 120 SFC/
105 cells). These PRAME-CTLs were also able to target autolo-
gous tumor blasts (57 6 6 IFNg SFC/105), demonstrating that
the same peptides were presented physiologically. A Cr51 release
assay confirmed that the PRAME-reactive T cells were cytotoxic,
lysing autologous-PHA blasts loaded with PRAME-library (63 6
14% at a 20:1 E:T ratio), but not with irrelevant library. Using sub-
pools, we found that the responses of our expanded PRAME-CTLs
were polyclonal, since they consistently released IFNg in response
to 1 to 6 pentadecapeptides pools. Moreover, this approach has al-
lowed to identify 6 potential new immunogenic 15mer peptides
that are processed and presented by tumor cells, and should facili-
tate expansion of polyclonal PRAME-CTLs for adoptive transfer
in patients with PRAME1 malignancy.156
GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND
REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS
OF HLA-IDENTICAL SIBLING TRANSPLANTS
Olsson, R., Remberger, M., Mattsson, J., Hassan, Z., Ringden, O.
Karolinska University Hospital, Stockholm, Sweden
Four doses of methotrexate (MTX) and low-dose cyclosporine
(CsA), starting at 1 mg/kg/day i.v. with early discontinuation, were
given to 171 consecutive HLA-identical sibling recipients with leu-
kaemia. Apart from MTX, retrospective controls (n 5 40) received
CsA starting at 5–7.5 mg/kg/day i.v., and discontinued 1 year post-
transplant. The target CsA trough levels were 100 ng/ml and 200–
300 ng/ml in the low-dose and the control group, respectively. In
the low-dose group, the risk of acute GVHD grades I-II was aug-
mented (66% vs. 49%, p\0.01), whereas grades III-IV did not differ
between the groups (9% vs. 8%). The risk of chronic GVHD was
markedly increased in those receiving low-dose CsA (50% vs.
29%, p\ 0.01), and the cumulative proportion of relapse at 5 years
post-transplant was increased in the control group (51% vs. 26%,
p\ 0.01). Moreover, the 5-year survival rate was 63% in the low-
dose group compared to 40% in the controls (P5 0.04). In a multi-
variate analysis, low-dose CsA was the only factor associated with
acute GVHD grades I-IV (RH 2.40, P 5 0.02). Significant predic-
tors of chronic GVHD were low-dose CsA (RH 2.56, p\ 0.01),
chronic myeloid leukaemia (RH 1.92, p\0.01), and administration
of donator lymphocyte infusions (RH 1.66, P5 0.03). The risk of re-
lapse was counteracted by chronic GVHD (RH 0.46, p \ 0.01),
whereas chronic GVHD (RH 0.53, p \ 0.01) and acute GVHD
grades III-IV (RH 4.35, p\0.01) were the strongest factors associ-
ated with patient death. Importantly, the transplant-related mortal-
ity at 5 years post-transplant was similar in the low-dose CsA and
control groups (18% and 20%, respectively, P 5 0.58). In conclu-
sion, a low-dose CsA regimen in leukemic recipients of HLA-iden-
tical sibling transplants increases the rate of chronic GVHD,
which seems to attenuate the risk of relapse, thereby improving pa-
tient survival.157
ISOLATED EXTRA-MEDULLARY RELAPSE OF ACUTE LEUKEMIA AFTER
ALLOGENEIC STEM-CELL TRANSPLANTATION (SCT); DIFFERENT KINET-
ICS AND BETTER PROGNOSIS THAN SYSTEMIC RELAPSE
Shimoni, A., Rand, A., Shem-Tov, N., Yerushalmi, R., Hardan, I.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic SCT is a potentially curative treatment for acute leu-
kemia, however relapsing disease is the major cause of treatment
failure. Isolated extramedullary (IEM) relapse is considered a rare
event and its characteristics and prognosis are less defined than sys-
temic relapse. We analyzed outcomes of 356 consecutive pts with
AML/MDS (n 5 277) and ALL (n 5 79) given SCT in a single in-
stitution. With a median follow-up of 30 months (range, 1–103),
149 pts relapsed (122 died). The overall survival rate was 34%
(95CI, 27–41) and the cumulative incidence of relapse 47%(95CI, 42–54). 17 pts had IEM relapse (11.4% of all first relapses);
CNS (n 5 6), mediastinum (n 5 2), pleura (n 5 2), skin (n 5 2),
breast (n 5 2), bone (n 5 1), other soft tissue masses (n 5 2).
IEM relapse occurred later after SCT than systemic relapse; me-
dian 14 (1–38) and 3 (1–59) months, respectively (p 5 0.002). Pts
with an IEM relapse were younger, median age 38 and 46 years, re-
spectively (p 5 0.02). IEM relapse occurred more commonly in
ALL (23% of relapses) than MDS/AML (8%, P 5 0.02). There
was a trend for higher incidence in pts transplanted in remission
(16% of relapses) than in pts transplanted in active disease (8%,
p 5 0.09). There was no relation to donor or conditioning type. In-
terestingly, among 14 pts having IEM relapse more than 3 months
after SCT, 11 had a history of chronic GVHD (79%), compared
with 29 of 70 pts with systemic relapse (41%, p 5 0.01). Pts with
IEM relapse were most often treated with systemic chemotherapy,
followed by radiation therapy and DLI when feasible. Pts with sys-
temic relapse were treated with chemotherapy and DLI or a second
SCT. Among the 17 pts with IEM relapse, 12 achieved CR (71%),
5 remained in continuous CR, 7 relapsed again, 2 systemic (both
died), 5 EM (2 are in long-term remission). Among the 132 pts
with systemic relapse, 35 achieved CR (27%), 14 died in remission,
7 remained in continuous CR, 14 relapsed again, 9 systemic (all
died), 5 EM (1 is in long-term remission). The median survival af-
ter relapse was 2.5 and 20 months, and the 2-year OS rates 7% and
38% after systemic and IEM relapse, respectively (p 5 0.0002). In
conclusion, IEM relapse of acute leukemia after SCT is relatively
common. It occurs later than systemic relapse and more commonly
in pts with chronic GVHD, suggestive that GVL is able to prevent
systemic recurrence but is less successful in EM sites. When treated
aggressively prognosis is better with IEM relapse and long-term
survival is feasible.158
CONDITIONING REGIMENS PRIOR TO ALLOGENEIC STEM-CELL TRANS-
PLANTATION (SCT) IN ACUTE LEUKEMIA: THE ROLE OF DOSE INTENSITY
Shimoni, A., Rand, A., Hardan, I., Shem-Tov, N., Yerushalmi, R.,
Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer, Israel
Allogeneic SCT with both myeloablative and reduced-intensity
conditioning (RIC) is effective therapy in acute leukemia. To better
define the role of dose intensity in SCT, we retrospectively ana-
lyzed SCT outcomes in 356 consecutive adult patients (pts) with
MDS/AML (n 5 277) and ALL (n 5 79) given SCT over an 8-
year period in a single institution. The median age was 51 (range,
17–75). The donors were HLA-matched siblings (n 5 191),
matched unrelated (n 5 139) and alternative (n 5 26). Pts meeting
standard eligibility criteria were routinely given myeloablative con-
ditioning (MAC, Cy/TBI or BuCy, n 5 141). Pts non-eligible for
MAC were given either RIC (fludarabine and reduced doses of bu-
sulfan or melphalan, n 5 116) or modified myeloablative condi-
tioning (modMAC, fludarabine with myeloablative doses of
busulfan or treosulfan, n 5 99). Disease status at SCT was CR1/
CR2 (n 5 176), previously untreated or untreated relapse (n 5
63) and chemo-refractory (n 5 117). With a median follow-up of
30 months (range 1–103), 159 pts are alive and 197 died; 75 of
treatment-related causes and 122 of relapse. The estimated 5-yr
overall survival (OS) in this relatively high-risk pt group was
34% (95%CI, 27–41). The status of disease at SCT was the most
important factor predicting OS; 48, 31 and 16% for pts in CR, un-
treated or chemo-refractory leukemia, respectively (p\0.001). Mul-
tivariable analysis (MVA) identified SCT not in CR, SCT from
unrelated and alternative donors as adverse prognostic signs with
hazard ratios (HR) of 2.7, 1.5, and 2.2, respectively. The condition-
ing regimen used was not a significant factor in the whole pt group
with 5-yr OS of 38, 35 and 31% after MAC, modMAC and RIC,
respectively (p 5 NS). However, RIC was associated with reduced
OS in 2 subgroups. Among pts with MDS/AML given SCT not in
CR, 5-yr OS was 34, 24 and 13% after MAC, modMAC and RIC,
respectively (p 5 0.03) with HR of 1.6 for RIC in MVA. In the
group of ALL pts, MVA identified RIC and SCT not in CR1 as
adverse prognostic signs with HR of 2.0 (p 5 0.04) and 2.0 (p 5
0.03), respectively. In conclusion, MAC should still be considered
the standard of care for SCT in acute leukemia in eligible pts.
RIC is associated with inferior outcome in pts with ALL and pts
60 Poster Session-Inot in CR at SCT. Randomized studies are needed to determine
the role of RIC in MDS/AML pts in CR at SCT. The novel mod-
MAC regimens are relatively well tolerated even in pts not eligible
for MAC and may be more effective than standard RIC in refrac-
tory disease.159
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (HCT) FOR PROLYM-
PHOCYTIC LEUKEMIA (PLL)
Kalaycio, M., Kukreja, M., Szer, J., Woolfrey, A., Cortes, J., Arora, M.
CIBMTR, Milwaukee, WI
Although PLL is indolent in some people, most affected persons
die within 1 year. Several case reports suggest a benefit to allogeneic
HCT.We sought to determine if this hypothesis is correct in the ob-
servational database of the Center for International Blood and Mar-
row Transplant Research.We retrospectively reviewed data from 47
subjects transplanted between1995 and 2006. Median age was 54 y
(range, 30–75 y). Karnofsky performance score was .80% in 30
(75%). Immunophenotype was B-cell in 11 (23%), T-cell in 21
(45%), and unknown in 15 (32%). Six patients (13%) had a splenec-
tomy and 16 (36%) were in complete remission (CR) at the time of
transplant. Donors were HLA-matched siblings or well-matched
unrelated donors in 34 (70%). Conditioning regimens included
high-doses of radiation or busulfan in 19 (40%), low-doses in 14
(30%), and neither in 14 (30%) includingmelphalan (N5 7) and flu-
darabine-containing regimens (N5 6). Grafts were blood cells in 31
(66%). Grade 2–4 acute graft versus host disease (GvHD) developed
in 52% (95% confidence interval (CI) 38–66%) of transplant recip-
ients. 1 year incidence of chronic GVHD was 42% (CI 28–57%).
Treatment related mortality (TRM) was 28% (CI 16–42%) and oc-
curred within 1 yr of transplant. Common causes of non-relapse
mortality were infection (N 5 4; 12%), GvHD (N 5 5; 15%), and
pneumonitis/ARDS (n 5 3;9%). PLL progression was the most
common cause of death (N 5 16; 49%). Median progression-free
survival (PFS) and overall survival (OS) is 5 and 11 mos, respectively.
Median PFS for 16 subjects transplanted in CR is 8.9 mo. Median
PFS for patients with matched siblings or well-matched donors
(N 5 34) is 5.2 mo. With a median follow-up of survivors of 13
mos, the 1y PFS and OS is 33% (CI 20–47%) and 48% (CI 33–
62%), respectively. At 2y, the PFS is also 33% (CI 20–47%) and
OS is 35% (CI 21–50%). These data provide information on antic-
ipated outcomes of allotransplants for PLL.160
PROLONGED SURVIVAL IN ADULTS WITH ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) FOLLOWING REDUCED INTENSITY CONDITIONING
WITH CORD BLOOD OR SIBLING DONOR TRANSPLANTATION
Bachanova, V., Verneris, M.R., Brunstein, C., Weisdorf, D. University of
Minnesota, Minneapolis,, MN
The optimal therapy for adult ALL patients.35 years or intoler-
ant of myeloablative allotransplantation is uncertain. Twenty-two
adult ALL patients received reduced intensity conditioning (RIC)
followed by allogeneic transplantation. All patients were high risk
with 64% having Ph1 ALL and 46% in $2nd remission, 20/22
were in cytogenetic CR. Following a uniform preparative regimen
(fludarabine 40 mg/m2/day  5, cyclophosphamide 50 mg/kg/day
and 200 cGy total body irradiation) patients received either umbilical
cord (UCB, n5 18) or matched related (MRD, n5 4) donor grafts.
All patients reached neutrophil engraftment (median 10 days) and
100% donor chimerism (median day 23). Overall survival, treatment
related mortality and relapse were 50% (95% confidence interval
[CI], 27–73%), 27% (95%CI, 9–45%), 36% (95%CI, 14–58%) at
3 years, respectively. There were no relapses beyond 2 years. OS,
TRM and relapse following cord blood HCT were 49% (95%CI,
23–75%), 28% (95%CI, 8–48%) and 33% (95%CI, 9–57%). The
cumulative incidence of acute (grade II-IV) and chronic graft versus
host disease was 55% and 45%.HCT inCR1 led to less TRM (8%vs
50%, p\0.04) and improved OS (81% vs 15%, p\0.01). For ALL
adults in CR1, RIC allografting using UCB or MRD results in
modest TRM, limited risk of relapse and promising leukemia-free
survival.161
ADOPTIVE T CELL THERAPY USING EDUCATED T CELLS GENERATED BY
THE SEQUENTIAL STIMULATION WITH DC/TUMOR FUSION CELLS AND
ANTI-CD3/CD28
Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Zarwan, C.1, Stone, R.2,
Bissonnette, A.2, Friedman, T.2, Stevenson, K.2, Neuberg, D.2,
Mills, H.1, Glotzbecker, B.1, Levine, J.D.1, Joyce, R.1, Boussiotis, V.1,
Tzachanis, D.1, Spentzos, D.1, Konstantinopoulos, P.1, Kufe, D.2,
Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston, MA;
2Dana Farber Cancer Institute, Boston, MA
Acute leukemia is susceptible to T cell mediated killing as evi-
denced by the graft versus disease effect following allogeneic trans-
plantation. The development of adoptive immunotherapy to more
selectively target tumor cells is an area of interest. Ligation of the
CD3/CD28 complex results in expansion of T cells ex vivo with
a phenotype that is dependent on the immunologic milieu during
stimulation. We have developed a cancer vaccine in which autolo-
gous tumor cells are fused with dendritic cells (DCs). We postu-
lated that stimulation with fusions followed by anti-CD3/CD28
would result in the expansion of activated T cells targeting tumor
antigens. Tumor was obtained from peripheral blood or bone mar-
row of patients with AML. DCs were generated from adherent
mononuclear cells cultured with rhIL-4, GM-CSF and TNFand
fused with tumor cells by coculture in polyethylene glycol. T cells
were stimulated by fusions prior to or following exposure to
antiCD3/CD28 antibody coated plates. Stimulation by fusions fol-
lowed by anti-CD3/CD28 resulted in the synergistic expansion of
T cells, manifested by a greater stimulation index (SI) compared
to stimulation by either pathway alone (SI 8.2 versus 3.3 with fu-
sions alone). A rise in CD41/CD251 cells was noted following se-
quential stimulation with fusions and anti-CD3/CD28 (9.3% vs.
2.7% with fusions alone). An higher percentage of CD41/
CD251 cells expressed IFNg when exposed to fusions followed
by anti-CD3/CD28 (7% compared to 2% with fusions alone). As
compared to un-stimulated T cells, stimulation with fusions or
anti-CD3/CD28 resulted in a 3.3 and 3.8 fold increase in CD81
T cells expressing granzyme B, respectively. In contrast, sequential
stimulation with fusions and anti-CD3/CD28 induced a 19-fold ex-
pansion of granzyme B1 cells consistent with enhanced cytolytic
capacity. In spectratyping analysis, T cells undergoing sequential
stimulation with fusions and anti-CD3CD28 demonstrate greater
skewing of CDR3-size usage in the T cell receptor as compared
to T cells stimulated by fusions or anti-CD3/CD28 alone. The pat-
tern of gene expression in T cells stimulated sequentially by fusions
and anti-CD3CD28 is being assessed. In conclusion, sequential
stimulation of T cells by fusions and anti-CD3/CD28 results in
the expansion of tumor reactive activated T cells. A clinical trial
evaluating the use of T cells generated by sequential stimulation
with DC/tumor fusions and anti-CD3CD28 for patients with acute
leukemia is planned.162
IMPAIRED PRE-TRANSPLANT FEV1 IS ASSOCIATED WITH REDUCED
OVERALL AND DISEASE FREE SURVIVAL FOLLOWING ALLOGENEIC
TRANSPLANT FOR ACUTE MYELOGENOUS LEUKEMIA
Magenau, J.1, Maslak, J.2, Mineishi, S.1, Digiandamenico, S.2,
Braun, T.1, Levine, J.E.1, Yanik, G.A.1 1University of Michigan, Ann
Arbor, MI; 2University of Michigan, Ann Arbor, MI
Introduction: Pulmonary function testing (PFT) is routinely per-
formed prior to allogeneic hematopoetic stem cell transplant
(HSCT), but its relationship to survival is poorly described. In this
report, the post-transplant survival outcomes of Acute Myelogenous
Leukemia (AML) patients are examined with respect to pre-trans-
plant pulmonary function.
Methods: Two hundred fifty one patients with AML receiving
HSCT between January 2001 and May 2008 at the University of
Michigan were retrospectively analyzed for pre-transplant PFTs by
forced expiratory volume at one second (FEV1), forced vital capacity
(FVC), and diffusion capacity (DLCO). PFT function parameters
FEV1 ($80% vs. \80%), FVC ($80% vs. \80%), and DLCO
($65% vs. \65%) were correlated with overall (OS) and disease
free survival (DFS). Using a multivariate Cox regression analysis,
OS and DFS were modeled for the following risk factors: age at
